No Data
Revenues Working Against Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Following 31% Dive
WHO Reportedly Greenlights Mpox Vaccine Purchases Before Approval
Emergent Biosolutions Price Target Announced at $16.00/Share by Rodman & Renshaw
Emergent Biosolutions Initiated at Buy by Rodman & Renshaw
Emergent BioSolutions Analyst Ratings
Express News | WHO: Côte D'Ivoire Reports First Cases Of Clade II Mpox Since The Start Of The Multi-Country Outbreak In 2022